138 related articles for article (PubMed ID: 38603834)
21.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
22. Identification and clinical validation of diverse cell-death patterns-associated prognostic features among low-grade gliomas.
Yang W; Yu H; Lei Q; Pu C; Guo Y; Lin L
Sci Rep; 2024 May; 14(1):11874. PubMed ID: 38789729
[TBL] [Abstract][Full Text] [Related]
23. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
24. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
25. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
Chen J; Li Y; Han X; Pan Y; Qian X
Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
[TBL] [Abstract][Full Text] [Related]
26. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
27. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
28. S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma.
Zhang Y; Yang X; Zhu XL; Bai H; Wang ZZ; Zhang JJ; Hao CY; Duan HB
Aging (Albany NY); 2021 Jun; 13(11):15459-15478. PubMed ID: 34148033
[TBL] [Abstract][Full Text] [Related]
29. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
30. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
[TBL] [Abstract][Full Text] [Related]
31. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
[TBL] [Abstract][Full Text] [Related]
32. Deciphering anoikis resistance and identifying prognostic biomarkers in clear cell renal cell carcinoma epithelial cells.
Li J; Cao Q; Tong M
Sci Rep; 2024 May; 14(1):12044. PubMed ID: 38802480
[TBL] [Abstract][Full Text] [Related]
33. Identification of the molecular subtypes and signatures to predict the prognosis, biological functions, and therapeutic response based on the anoikis-related genes in colorectal cancer.
Zhai X; Chen B; Hu H; Deng Y; Chen Y; Hong Y; Ren X; Jiang C
Cancer Med; 2024 May; 13(10):e7315. PubMed ID: 38785271
[TBL] [Abstract][Full Text] [Related]
34. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
35. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
36. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
Liu Z; Cheng X; Pang B; Wang S; Liu B; Cao C; Qian R; Liang W; Zhu Y; Li P; Gao Y
Int Immunopharmacol; 2022 Mar; 104():108399. PubMed ID: 35008004
[TBL] [Abstract][Full Text] [Related]
37. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
38. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
39. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
PeerJ; 2024; 12():e16874. PubMed ID: 38406287
[TBL] [Abstract][Full Text] [Related]
40. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]